// App-Quantinova.ai

194 : NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.

Researchers

Presenter

  • Jonathan R. Strosberg

Principal Investigators

  • Edward M. Wolin

  • Beth Chasen

  • Matthew H. Kulke

  • David L Bushnell

  • Martyn E. Caplin

  • Richard P. Baum

  • Pamela L. Kunz

  • Timothy J. Hobday

  • Andrew Eugene Hendifar

  • Kjell E. Oberg

  • Maribel Lopera Sierra

  • Dik J. Kwekkeboom

  • Philippe B. Ruszniewski

  • Eric Krenning

Medical Centers

  • Moffitt Cancer Center, Tampa, FL

  • University of Kentucky, Lexington, KY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Veterans Administration Medical Center, Iowa City, IA

  • The Royal Marsden Hospital, London, United Kingdom

  • Zentralklinik Bad Berka, Bad Berka, Germany

  • Stanford School of Medicine, Stanford, CA

  • Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • Uppsala University Hospital, Uppsala, Sweden

  • Advanced Accelerator Applications, New York, NY

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Beaujon Hospital, Clichy, France

  • Erasmus University Medical Center, Rotterdam, Netherlands

Locations

  • United States

  • United Kingdom

  • Germany

  • Sweden

  • Netherlands

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • Protein Tyrosine Phosphatase, Receptor Type F

Drug/Treatment

  • Somatostatin

  • Lu-DOTATATE

  • Octreotide

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT01578239

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved